Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 4

BRAINSTORM CELL THERAPE Form 4 October 25, 2007	JTICS INC		
			OMB APPROVAL
UNITED STAT	ES SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION	OMB 3235-0287 Number:
Section 16. Form 4 or Form 5 obligations may continue. Filed pursuant Section 17(a) of t	OF CHANGES IN BENEFICIAL OV SECURITIES to Section 16(a) of the Securities Excha he Public Utility Holding Company Act (h) of the Investment Company Act of 1	nge Act of 1934, of 1935 or Section	January 31 Expires: 2005 Estimated average burden hours per response 0.5
(Print or Type Responses)			
1. Name and Address of Reporting Person ARBEL IRIT	 2. Issuer Name and Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC [BCLI] 	Issuer	Reporting Person(s) to all applicable)
(Last) (First) (Middle) C/O BRAINSTORM CELL THERAPEUTICS INC., 110 EAST 59TH STREET	3. Date of Earliest Transaction (Month/Day/Year) 10/23/2007	X Director Officer (give to below)	itle 10% Owner Other (specify below)
(Street) NEW YORK, NY 10022	4. If Amendment, Date Original Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by Or	int/Group Filing(Check ne Reporting Person ore than One Reporting
(City) (State) (Zip)	Table I - Non-Derivative Securities A		or Beneficially Owned
(Instr. 3) any		5. Amount of 6. Securities For Beneficially (D Owned (I)	Ownership 7. Nature of orm: Direct Indirect O) or Indirect Beneficial
Reminder: Report on a separate line for each	h class of securities beneficially owned directly	or indirectly.	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative Expiration Date Underlying Securities (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities Acquired (A) or (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Code V (A) Title (D) Date Expiration Amount Exercisable Date Number Shares Stock Option 100,000 Common 07/01/2007 07/01/2017 \$ 0.15 10/23/2007 F 100,00 (1) (right to Stock buy) **Reporting Owners**

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 4

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
ARBEL IRIT C/O BRAINSTORM CELL THERAPEUTICS INC. 110 EAST 59TH STREET NEW YORK, NY 10022		Х				
Signatures						
/s/ Irit Arbel	10/25/2007					
*****	_					

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

As a result of an administrative error, the Board of Directors of the issuer approved the grant of a stock option to purchase 100,000 shares (1) of common stock of the issuer to Mr. Arbel in July 2007. Mr. Arbel agreed to relinquish and cancel the stock option which was granted to him as a result of such error.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.